Patents Assigned to Bayer Corporation
  • Patent number: 8486995
    Abstract: Disclosed is a method of controlling insects or acarids comprising contacting crops or their environment with a compound of the formula (I): and least one compound selected from the group consisting of: bifenazate, fenpyroximate pyridaben, fenazaquin, abamectin, emamectin benzoate, fenpropathrin and propargite.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: July 16, 2013
    Assignee: Bayer Corporation
    Inventors: Reiner Fischer, Emmanuel Salmon, Heike Hungenberg, Jingquan Guo
  • Patent number: 7723102
    Abstract: A mammalian cell gene expression vector system comprising (a) an episomal maintenance system (b), a strong promoter/enhancer, (c) a protein transactivation system and (d) DNA coding for a heterologous protein. The episomal maintenance and protein transactivation systems can include sub-elements located on the same or different plasmids within the cell expression system.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: May 25, 2010
    Assignee: Bayer Corporation
    Inventors: Myung-Sam Cho, Helena Yee
  • Patent number: 7507714
    Abstract: This invention provides novel peptides that function in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent fashion. These insulin secretagogue peptides are shown to stimulate insulin release in rat islet cells in vitro, and in vivo. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, in particular type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP/PACAP-related polypeptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the insulin secretagogue peptides to said mammal. Also disclosed are methods of making the peptides, both recombinant and synthetic.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: March 24, 2009
    Assignee: Bayer Corporation
    Inventors: Clark Pan, Manami Tsutsumi, Armen B. Shanafelt
  • Patent number: 7410784
    Abstract: Enzyme activity sensors comprising a planar waveguide can be used for sensitive and quantitative measurement of enzyme activity. Such enzyme activity sensors are useful in a variety of settings, including clinical, commercial, and public health settings.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: August 12, 2008
    Assignee: Bayer Corporation
    Inventor: Richard B. Hatch
  • Publication number: 20080131328
    Abstract: An indicator for enabling an analytical instrument to positively detect the presence of a vial in respective vial-receiving rack position regardless of whether the vial is oriented in a manner necessary for a code reader to read a code printed on the vial. Translation of a leaf spring upon insertion of a vial into a rack position causes a flag to obscure a code provided adjacent the rack position. An instrument into which the rack is installed interprets the failure of the code reader to detect this code as positive indication that a vial is disposed within the respective rack position.
    Type: Application
    Filed: May 24, 2005
    Publication date: June 5, 2008
    Applicant: BAYER CORPORATION
    Inventors: Alexander Schutt, Martin Trump
  • Patent number: 7285640
    Abstract: The present invention provides human antibodies specific for stem cell factor that contain at least one CDR derived from a combinatorial antibody library. The invention also provides pharmaceutical compositions comprising the antibodies and methods of treating asthma. The invention further provides methods of detecting stem cell factor using the antibodies.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: October 23, 2007
    Assignee: Bayer Corporation
    Inventors: Toshihiko Takeuchi, Adrian Tomkinson, Steven Neben
  • Publication number: 20070167611
    Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.
    Type: Application
    Filed: March 9, 2007
    Publication date: July 19, 2007
    Applicants: Bayer Corporation, The Wistar Institute
    Inventors: Thanos Halazonetis, Wolfgang Hartwig
  • Patent number: 7211398
    Abstract: This invention relates to novel human genes, to proteins expressed by the genes, and to variants of the proteins. The invention also relates to diagnostic assays and therapeutic agents related to the genes and proteins, including probes, antisense constructs, and antibodies. The subject nucleic acids have been found to be differentially regulated in tumor cells, particularly in colon cancer tissue.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: May 1, 2007
    Assignees: Bayer Corporation, Mayo Foundation for Medical Education and Research
    Inventors: Jon H. Astle, Christopher C. Burgess, Theodore J. Catino, Poornima Dwivedi, Marcia E. Lewis, Gary A. Molino, Susan H. Myerow, Arunthathi Thiagalingam, Stephen Thibodeau, Lawrence J. Burgart, Lisa Allyn Boardman
  • Patent number: 7198929
    Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: April 3, 2007
    Assignees: Millennium Pharmaceuticals, Bayer Corporation
    Inventors: William James Cook, Rosana Kapeller-Libermann, Helga Rubsamen-Waigmann, Frank Spaltmann
  • Patent number: 7189801
    Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360–386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: March 13, 2007
    Assignees: The Wistar Institute, Bayer Corporation
    Inventors: Thanos Halazonetis, Wolfgang Hartwig
  • Patent number: 7182912
    Abstract: An analyzer for performing automated assay testing. The analyzer includes a storage and conveyor system for conveying cuvettes to an incubation or processing conveyor, a storage and selection system for test sample containers, a storage and selection system for reagent containers, sample and reagent aspirating and dispensing probes, a separation system for separating bound from unbound tracer or labeled reagent, a detection system and date collection/processing system. All of the subunits of the machine are controlled by a central processing unit to coordinate the activity of all of the subunits of the analyzer. The analyzer is specifically suited for performing heterogeneous binding assay protocols, particularly immunoassays.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: February 27, 2007
    Assignee: Bayer Corporation
    Inventors: Glen Carey, Scott C. Lewis, Mary Beth Whitesel, Frank C. Klingshirn
  • Patent number: 7163616
    Abstract: Reagents for detecting an analyte are described. A reagent comprises (a) an enzyme selected from the group consisting of a flavoprotein, a quinoprotein, and a combination thereof; and (b) a mediator selected from the group consisting of a phenothiazine, a phenoxazine, and a combination thereof. In addition, reagents having good stability to radiation sterilization are described. Electrochemical sensors and sampling devices comprising such reagents, methods of producing a sterilized device including such reagents, and methods for detecting an analyte which utilize such reagents are described as well.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: January 16, 2007
    Assignee: Bayer Corporation
    Inventors: Mark S. Vreeke, Mary Ellen Warchal-Windham, Christina Blaschke, Barbara J. Mikel, Howard A. Cooper
  • Patent number: 7157056
    Abstract: A sample introduction device is provided that is particularly useful in the critical care environment for the anaerobic withdrawal of small volumes of arterial blood from a sample collection syringe and introduction thereof into a sample chamber of a sensor for analysis. The sample introduction device includes a Luer fitting adapted to mate an outlet of the container in a concentric orientation with an input aperture of the sample chamber. A tubular probe is adapted for concentric placement with both the outlet and inlet aperture, with a first end thereof extending into the syringe and a second end adapted for attachment to an air supply. The probe has a predetermined diameter sufficient to provide an annular clearance between the probe and each of the outlet and inlet aperture. A predetermined volume of air is injected through the probe into the container to displace a predetermined volume of sample therefrom, through the annular clearance into the sample chamber.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: January 2, 2007
    Assignee: Bayer Corporation
    Inventor: Kevin J. Sullivan
  • Publication number: 20060202179
    Abstract: A chemiluminescent substrate of a hydrolytic enzyme having the following general Formula I is disclosed, as follows: Lumi-M-P ??Formula I where “Lumi” is a chemiluminescent moiety capable of producing light (a) by itself, (b) with MP attached and (c) with M attached. Examples of Lumi include chemiluminescent acridinium compounds, benzacridinium compounds, quinolinium compounds, isoquinolinium compounds, phenanthridinium compounds, and lucigenin compounds, spiroacridan compounds, luminol compounds and isoluminol compounds. M is a multivalent heteroatom having at least one lone pair of electrons selected from oxygen, nitrogen and sulfur, directly attached to the light emitting moiety of Lumi at one end and to P at the other end. P is a group that can be readily removed by hydrolytic enzymes. An enzymatic reaction utilizing the above compound is the following: where HE is a hydrolytic enzyme. Lumi-M is a chemiluminescent product having physical and/or chemical properties different from those of Lumi-M-P.
    Type: Application
    Filed: June 5, 2006
    Publication date: September 14, 2006
    Applicant: BAYER CORPORATION
    Inventors: Qingping Jiang, Anand Natrajan, David Sharpe, Wen-Jee Wong, Say-Jong Law
  • Patent number: 7094811
    Abstract: Energy absorbing flexible foams can be produced by reacting an isocyanate with a first polyol, prepared at least in part by an active double metal cyanide catalyst and a second polyether polyol is prepared at least in part by a basic or acidic catalyst.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: August 22, 2006
    Assignee: Bayer Corporation
    Inventors: Neil H. Nodelman, David A. Radovich, Albert Magnotta, Carl E. Holsinger
  • Patent number: 7091323
    Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: August 15, 2006
    Assignees: Bayer Corporation, Bayer Aktiengesellschaft
    Inventors: Clark Pan, Andreas M. Knorr, Michael Schauer, Claudia Hirth-Dietrich, Sabine Kraft, Barbara Krebs
  • Patent number: 7037671
    Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: May 2, 2006
    Assignees: Millennium Pharmaceuticals, Inc., Bayer Corporation
    Inventors: William James Cook, Rory A. J. Curtis, Frank Spaltmann
  • Patent number: 7033758
    Abstract: Methods are provided for highly sensitive and rapid in situ detection of a nucleic acid analyte of a known sequence. The method employs oligonucleotide probes in a series of optimized steps to amplify a signal and decrease background. Sensitivity is enhanced such that the method can detect as few as 1–2 copies of nucleic acid analyte per sample, the sample containing a cell, tissue or similar biological material. Methods of detecting and identifying the position of the nucleic acid analyte in a cell are also provided.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: April 25, 2006
    Assignee: Bayer Corporation
    Inventors: Daryn Kenny, Lu Ping Shen, Vincent P. Antao, Audrey N. Player, Wei Cao
  • Patent number: 7019123
    Abstract: The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: March 28, 2006
    Assignee: Bayer Corporation
    Inventors: Paul P. Tamburini, Gary Davis, Katherine A. Delaria, Christopher W. Marlor, Daniel K. Muller
  • Patent number: 7001737
    Abstract: Disclosed is an assay for determining the presence and concentration of trypsin inhibitor in urine samples. The assay reagents, which may be used either in the liquid or dry states, include trypsin, a trypsin substrate and a polycarboxylic chelating agent. The inclusion of the chelating agent in the assay has been found to reduce variation in the assay results.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: February 21, 2006
    Assignee: Bayer Corporation
    Inventors: Gary E. Rehm, Michael J. Pugia, Paul F. Corey